Janson Beckett Participates In ERSP Forum
New York, NY – October 14, 2005 – The Electronic Retailing Self-Regulation Program (ERSP) announced that Janson Beckett Cosmeceuticals (Janson Beckett), marketers of AlphaDerma CE anti-aging treatment, have provided support for broad comparative claims as to the ease of use of their product compared to Botox. However, ERSP has asked that Janson Beckett modify general performance, establishment, and testimonial, and specific comparative claims in online advertising. The marketer’s advertising was reviewed pursuant to an anonymous competitive challenge.
ERSP, the electronic direct-response industry’s self-regulatory forum supervised by the National Advertising Review Council (NARC), asked Janson Beckett to provide substantiation for core claims in the advertising for its AlphaDerma CE anti-aging treatment, including:
“Quickly Remove[s] Fine Lines & Wrinkles.”
Alpha Lipoic Acid is “clinically proven … to repair aged skin while preventing future damage.”
“AlphaDerma CE is the best, safest alternative to Botox.”
“I have been using your AlphaDerma Prep, Eye, and lotion treatment for two months and I am ecstatic to say that it really does work better than Botox.”
ERSP determined that the general performance claims communicated in a categorical, non- qualified context were not supported. However, generally accepted information on some of the ingredients contained in AlphaDerma CE provided adequate support for Janson-Beckett to communicate in its advertising, in a qualified context, that its product “may help” or “can assist” in the reduction or alleviation in the appearance of fine lines and wrinkles. ERSP acknowledged that the marketer has provided clinical proof of the efficacy of a 10% argireline formula but did not confirm that the other ingredients in AlphaDerma CE were tested at the same formulation contained in the advertised product. In the absence of such information, ERSP recommended that the marketer modify its claims that the effectiveness of the ingredients other than argireline has been “clin ically proven.”
ERSP did not object to marketer referring to its product as an easier-to-use and less painful wrinkle -reducing option than Botox. ERSP did recommend, however, that Janson Beckett — in the absence of comparative data related to Botox procedures or other significant competitors in the anti-aging formulation industry – modify any comparative performance claims.
ERSP also suggests that Janson Beckett consider adding statements at the top of its testimonial home page to clarify that results of the product vary and that consumer testimonials are not the opinion of Janson Beckett. Finally, ERSP agreed with the marketer that a doctor’s testimonial is more a doctor’s endorsement of the product as opposed to a customary “doctors recommend”
claim and also concurred with Janson Beckett that the testimonial claim referring to AlphaDerma
CE as “liquid gold” is statement of puffery.
In response to the ERSP decision, Janson Beckett represented that it “…appreciates ERSP’s conclusion that there is adequate support for qualified claims that AlphaDerma CE ‘may help’ or
‘can assist’ in the reduction or alleviation in the appearance of fine lines and wrinkles. … Moreover, Janson Beckett understands the degree of substantiation generally accepted as sufficient to support categorical performance, establishment, and comparative claims. With all this in mind, Janson Beckett will review and modify its advertisement for AlphaDerma CE as appropriate. … Janson Beckett is committed to fair and truthful advertising and is pleased to have participated in the ERSP self-regulatory process.”
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
NAD Finds Certain Claims for Mott’s Fruit Flavored Snacks Supported or Outside NAD’s Jurisdiction; Recommends General Mills Discontinue or Modify Other Claims
New York, NY – November 25, 2024 – The National Advertising Division recommended that General Mills discontinue or modify certain express and implied claims regarding the fruit and vegetable content of Mott’s Fruit Flavored Snacks and the nutritional benefits of those ingredients.
In National Advertising Division Challenge, Drip Hydration Voluntarily Discontinues Claims for its Ketamine IV Therapy
New York, NY – November 22, 2024 – Following a challenge brought by the National Advertising Division as part of its routine monitoring program, Drip Hydration voluntarily discontinued advertising claims for its Drip Hydration Ketamine IV Therapy.
NAD Finds Patented and Safety Claims for POOPH’s Pet Odor & Stain Eliminator Supported; Recommends Other Claims Be Modified or Discontinued
New York, NY – November 21, 2024 – The National Advertising Division determined that Ikigai supported patented and safety claims for their POOPH Pet Odor & Stain Eliminator, but recommended that other claims, including claims that POOPH eliminates odors and strains, be discontinued.
National Advertising Division Recommends SharkNinja Discontinue Certain Best Deep Carpet Cleaning Claims
New York, NY – November 19, 2024 – BBB National Programs’ National Advertising Division recommended that SharkNinja discontinue the claim “The Best Deep Carpet Cleaning Among Full-Sized Deep Carpet Cleaners** Based on ASTM F2828 vs. full-sized carpet cleaners above 14 lbs.”